

**End point title:** Number of Subjects With Sustained Accumulation of Disability (SAD) Before and After Alemtuzumab Treatment: 2 Year Comparison

<b>Statistical analysis title</b>	Switch CAMMS323/03409 (Pre Alemtuzumab)
Statistical analysis description	The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method.
Comparison groups	IFNB1a/Alemtuzumab Switch CAMMS323/03409 (Pre Alemtuzumab)
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	superiority
Method	
Parameter type	Percentage with SAD
Point estimate	9.35
Confidence interval	
level	95%
sides	2-sided
lower limit	5.54
upper limit	15.56
<b>Statistical analysis title</b>	Switch CAMMS323/03409 (Post Alemtuzumab)
Statistical analysis description	The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method.
Comparison groups	IFNB1a/Alemtuzumab Switch CAMMS323/03409 (Post Alemtuzumab)
Number of subjects included in analysis	139
Analysis specification	Pre-specified
Analysis type	superiority
Method	
Parameter type	Percentage with SAD
Point estimate	7.95
Confidence interval	
level	95%
sides	2-sided
lower limit	4.48
upper limit	13.9
<b>Statistical analysis title</b>	Switch CAMMS324/03409 (Pre Alemtuzumab)
Statistical analysis description	The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method.
Comparison groups	IFNB1a/Alemtuzumab Switch CAMMS324/03409 (Pre Alemtuzumab)

Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
Method	
Parameter type	Percentage with SAD
Point estimate	20.42
Confidence interval	
level	95%
sides	2-sided
lower limit	14.67
upper limit	28.03
<b>Statistical analysis title</b>	Switch CAMMS324/03409 (Post Alemtuzumab)
Statistical analysis description	The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method.
Comparison groups	IFNB1a/Alemtuzumab Switch CAMMS324/03409 (Post Alemtuzumab)
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	superiority
Method	
Parameter type	Percentage with SAD
Point estimate	11.99
Confidence interval	
level	95%
sides	2-sided
lower limit	7.63
upper limit	18.58